Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
June 29, 2020 08:45 ET
|
Lantern Pharma
The machine learning-powered RADR® platform identifies genomically distinct cancer subtypes, and patient groups, that can respond to specific drugs that Lantern and its partners are developingThe...
Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
June 17, 2020 09:23 ET
|
Lantern Pharma
DALLAS, June 17, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic...
Lantern Pharma Announces Closing of Initial Public Offering
June 15, 2020 15:53 ET
|
Lantern Pharma
DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning...
Lantern Pharma Announces Pricing of Initial Public Offering
June 10, 2020 19:07 ET
|
Lantern Pharma
DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and...
Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
December 17, 2019 08:30 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of David Margrave as Chief...
Lantern Pharma Expands and Strengthens Board of Directors with Healthcare and Pharma Industry Veterans Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D.
December 11, 2019 09:00 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of two new members, Franklyn...
Lantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston
November 07, 2019 08:00 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI, machine learning (ML) and genomics, today announced its Chief Executive...
Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs
October 29, 2019 08:00 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected...
Lantern Pharma CEO Panna Sharma to Speak at Bio Data World West 2019
October 07, 2019 08:00 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced its Chief Executive Officer, Panna Sharma,...
Lantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments
October 01, 2019 08:00 ET
|
Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced a collaboration agreement with the...